1. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson by Joshua J. Field, Gene Lin, Maureen M. Okam, Elaine Majerus, Jeffrey Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, and David G. Nathan Blood Volume 121(17):3329-3334 April 25, 2013 ©2013 by American Society of Hematology

2. Phospho-NF-κB p65, A2AR, and IFN-γ expression in iNKT cells of controls and patients in steady state and pVOC (stages 2 and 3, respectively) at time 0 (preinfusion). Joshua J. Field et al. Blood 2013;121:3329-3334 ©2013 by American Society of Hematology

3. Phospho-NF-κB p65 expression in iNKT cells in subjects who received a 1.44 μg/kg/h regadenoson infusion for 24 hours with a 6-hour observation period when no drug was infused. Joshua J. Field et al. Blood 2013;121:3329-3334 ©2013 by American Society of Hematology

4. Pharmacokinetics of regadenoson infused for 12 hours during stage 1. Joshua J. Field et al. Blood 2013;121:3329-3334 ©2013 by American Society of Hematology